FIDELIS MOSERI: Open Payments
NPI 1275916611 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,158 in 52 payments from 7 companies in 2025. Trend: 2023 $1,280 · 2024 $777 · 2025 $1,158
Food & beverage: $1,158
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $333 |
| Otsuka America Pharmaceutical, Inc. | 15 | $313 |
| Alkermes, Inc. | 8 | $201 |
| E.R. Squibb & Sons, L.L.C. | 9 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $87 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
Products named: VRAYLAR, REXULTI, ARISTADA, COBENFY, CAPLYTA, ABILIFY ASIMTUFII, Auvelity, INGREZZA.
Industry payments across NV — which companies pay providers there.
